Pediaric Cancer Genome Project Makes Data Available To All

The Pediatric Cancer Genome Project has released the full genomes of over 500 normal and cancerous tumor tissue samples, with a view towards encouraging research against childhood cancers. Instantly, the wealth of knowledge on whole genome data doubles with this release.

Of the some 10,000 childhood cancer diagnoses made annually in the United States, over half affect the central nervous system (including the brain) as well as leukemias. According to National Cancer Institute statistics, up to 1,500 chlidren succumb to cancer each year.

Genome data will benefit many fields

While the genomic information likely most benefits cancer researchers, in fact scientists from many medical fields will benefit from this information.

In a press release, Dr. James Downing, the scientific director of St. Jude Children's Research Hospital, wrote:

"This effort has generated more discoveries than we thought possible. We want to make this information available to the broader scientific community so that, collectively, we can explore new treatment options for these children. By sharing the information even before we analyze it ourselves, we're hoping that other researchers can use this rich resource for insights into many other types of diseases in children and adults."

The almost entirely privately funded Cancer Genome Project costing $65 million, was initially launched in 2010. The data appears in the current issue of the journal Nature Genetics.

Source: PCGP

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap